HOWL — Werewolf Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $292.59m
- $197.57m
- $19.94m
- 31
- 15
- 76
- 35
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 17.9 | 92.6 | 158 | 129 | 134 |
Net Total Receivables | — | — | — | 6.93 | 1.35 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 18.1 | 92.9 | 161 | 140 | 138 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.41 | 3.12 | 16.3 | 17.5 | 14.8 |
Other Long Term Assets | |||||
Total Assets | 21.7 | 96.4 | 179 | 160 | 175 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.04 | 5.28 | 11.9 | 24 | 19.4 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 11.9 | 7.18 | 26.5 | 37.9 | 63.5 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 9.77 | 89.2 | 153 | 122 | 111 |
Total Liabilities & Shareholders' Equity | 21.7 | 96.4 | 179 | 160 | 175 |
Total Common Shares Outstanding |